The screening of prostate cancer in 2009: Overview of the oncology committee of the French Urological Association;Le dépistage du cancer de la prostate en 2009 : mise au point du comité de cancérologie de l'Association française d'urologie

Progres en Urologie

Volumn 20, Issue 1, 2010, Pages 17-23

  Peyromaure, M ^a   Beuzeboc, P ^a   Salomon, L ^b   Richaud, P ^c   Coloby, P ^d   Malavaud, B ^e   Rebillard, X ^f   Rischmann, P ^e   Villers, A ^g   Soulie, M ^e  

^a université Paris Cité   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c INSTITUT BERGONIÉ   (France)

^d CENTRE HOSPITALIER RENÉ DUBOS   (France)

^e CHU RANGUEIL   (France)

^f Service d'urologie   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Detection; Diagnosis; Prostate cancer; PSA; Screening

Indexed keywords

HUMAN; MALE; MORTALITY; PRACTICE GUIDELINE; PROSTATE TUMOR; SHORT SURVEY;

HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS;

EID: 73849106684     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2009.09.033     Document Type: Short Survey

References (21)

1. Rebillard X., Trétarre B., and groupe Francim. Épidémiologie des cancers urologiques en France. Rev Prat 57 (2007) 595-602
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 59 4 (2009) 225-249 [Epub 2009 May 27]
3. Hill C., and Doyon F. La fréquence des cancers en France : mortalité en 2003, évolution depuis 1968 et cancers de l'enfant. Bull Cancer 94 (2007) 7-13
4. Bossard N., Velten M., Remontet L., Belot A., Maarouf N., Bouvier A.M., et al. Survival of cancer patients in France: a population-based study from the Associations of the french cancer registries (Francim). Eur J Cancer 43 (2007) 149-160
5. Ries L.A.G., Melbert D., Krapcho M., Stinchcomb D.G., Howlader N., Horner M.J., et al. SEER cancer statistics review, 1975-2005. Surveillance, epidemiology, and end results (2008), National Cancer Institute, Bethesda, Md
6. Recommandations CCAFU 2007 - Cancer de la prostate. Étude scientifique sur l'état des lieux en France sur le dépistage individuel et le traitement initial du cancer de la prostate pour l'OPEPS : http://www.urofrance.org/fileadmin/user_upload/afu-info/2009-05-n38/OPEP S-etude-cancer-prostate.pdf.
7. Debré B. Rapport sur le dépistage du cancer de la prostate. OPEPS 2009.
8. Andriole G.L., Grubb III R.L., Buys S.S., Chia D., Church T.R., Fouad M.N., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 (2009) 1310-1319
9. Schröder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328
10. Roobol M.J., Kerkhof M., Schröder F.H., Cuzick J., Sasieni P., Hakama M., et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 56 (2009) 584-591
11. Jegu J., Tretarre B., Grosclaude P., Rebillard X., Bataille V., Malavaud B., et al. État des lieux et facteurs de participation à l'étude européenne ERSPC de dépistage randomisé du cancer de la prostate par dosage sérique de l'antigène prostatique spécifique : départements français du Tarn et de l'Hérault. Prog Urol 19 (2009) 487-500
12. Sennfält K., Sandblom G., Carlsson P., and Varenhorst E. Costs and effects of prostate cancer screening in Sweden-a 15-year follow-up of a randomized trail. Scand J Urol Nephrol 38 (2004) 291-298
13. Etzioni R., Penson D.F., Legler J.M., di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 94 (2002) 981-990
14. Draisma G., Boer R., Otto S.J., van der Cruijsen I.W., Damhuis R.A., Schröder F.H., et al. Lead times and overdetection duet o prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
15. Chun F.K., Suardi N., Capitanio U., Jeldres C., Ahyai S., Graefen M., et al. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. Eur Urol 55 (2008) 617-628
16. Bill-Axelson A., Holmberg L., Filén F., Ruutu M., Garmo H., Busch C., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100 (2008) 1144-1154
17. Bastian P.J., Carter B.H., Bjartell A., Seitz M., Stanislaus P., Montorsi F., et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 55 (2009) 1321-1332
18. Lucia M.S., Darke A.K., Goodman P.J., La Rosa F.G., Parnes H.L., Ford L.G., et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila Pa) 1 (2008) 167-173
19. Babaian R. Prostate cancer early detection. National comprehensive cancer network (NCCN). Practice guidelines in oncology, 2004, Vol 1.
20. Spurgeon S.E., Mongoue-Tchokote S., Collins L., Priest R., Hsieh Y.C., Peters L.M., et al. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy. Urology 69 (2007) 931-935
21. Eggener S.E., Yossepowitch O., Roehl K.A., Loeb S., Yu X., and Catalona W.J. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 71 (2008) 1016-1019